Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05478304

Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

This trial is a prospective, randomized, multicenter, multinational, blinded, superiority trial. The objective of this trial is to evaluate the effectiveness of left atrial appendage exclusion (LAAE) for the prevention of ischemic stroke or systemic arterial embolism in subjects undergoing cardiac surgery who have risk factors for atrial fibrillation and ischemic stroke.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Gold Coast University Hospital, Southport, Queensland, Australia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects ≥ 18 years of age
  • Documentation of any of the following clinical criteria:
  • CHA2DS2-VASc ≥ 4 with age ≥ 65
  • CHA2DS2-VASc ≥ 4 with significant left atrium enlargement or elevated NT-proBNP
  • CHA2DS2-VASc = 3 with age ≥ 75
  • CHA2DS2-VASc = 3 with significant left atrium enlargement or elevated NT-proBNP
  • CHA2DS2-VASc score = 2 with age ≥ 65 and significant left atrium enlargement or elevated NT-proBNP

Exclusion criteria

  • Clinically significant atrial fibrillation or atrial flutter:
  • Anytime in the past and
  • Documented by an electrocardiographic recording and
  • Episode lasting 6 minutes or longer1*
  • Prior procedure involving opening the pericardium or entering the pericardial space
  • Prior LAA occlusion, exclusion, or removal (surgical or percutaneous)
  • Planned cardiac surgical procedure using non-sternotomy approaches

o Partial sternotomies will be allowed.

  • Patients whose planned procedure is a heart transplant or implantation of any ventricular assist devices
  • Active endocarditis
  • Active systemic infection at the time of cardiac surgery requiring antibiotics, including known SARS-CoV2 infections regardless of symptoms
  • Known allergy to Nitinol or nickel sensitivity
  • Known medical condition with expected survival of less than 1 year
  • Other comorbidities that in the investigator's opinion make the subject unsuitable candidate to complete the protocol required visits.
  • Current enrollment in an investigation or trial or an investigational devices or investigational drug that would interfere with this trial.
  • Mental impairment or other psychiatric conditions which may not allow the patient to understand the nature, significance, and scope of the trial.
  • Pregnancy
  • Known severe symptomatic carotid disease

Treatment and study plan

AtriClip LAA Exclusion System

Device

LAAE using the AtriClip concomitant to and at the time of planned cardiac surgery

Primary outcomes

  1. Primary Effectiveness Endpoint

    Time frame: Common termination point (median follow-up for 5 years)

    Time to the first occurrence of ischemic stroke or systemic arterial embolism as adjudicated by the Clinical Events Committee (CEC), or any procedure wherein the LAA was excluded, occluded, or amputated following the index procedure.

  2. Primary Safety Endpoint

    Time frame: 30 days post index procedure

    Occurrence of at least one of the following events assessed through 30 days post index procedure:

    • Pericardial effusion requiring percutaneous or surgical treatment
    • Major bleeding attributable to index surgical procedure
    • Deep sternal wound infection
    • Myocardial infarction

Secondary outcomes

  1. Powered Secondary Effectiveness endpoint

    Time frame: Common termination point (median follow-up for 5 years)

    Time to the first occurrence of ischemic stroke or systemic arterial embolism

Sponsors and collaborators

Lead sponsor

AtriCure, Inc.

Industry

Collaborators

  • Population Health Research Institute

Registry information

Acronym: LeAAPS

Important dates

Study start
2023
Primary completion
2031
Study completion
2032
First posted
Jul 28, 2022
Registry last updated
Mar 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.